---
title: "Syndax Pharmaceuticals (SNDX) Receives a New Rating from a Top Analyst"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293182989.md"
description: "Barclays analyst Etzer Darout assigned a Buy rating to Syndax Pharmaceuticals (SNDX) with a $37 price target. Darout, a top 100 analyst with a strong track record, covers the healthcare sector. The current analyst consensus for SNDX remains a Strong Buy, with an average price target of $38.67."
datetime: "2026-07-20T07:57:21.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293182989.md)
  - [en](https://longbridge.com/en/news/293182989.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293182989.md)
generator: "portal-rs"
---

# Syndax Pharmaceuticals (SNDX) Receives a New Rating from a Top Analyst

Barclays analyst Etzer Darout assigned a Buy rating to Syndax Pharmaceuticals today and set a price target of $37.00.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

According to TipRanks, Darout is a top 100 analyst with an average return of 30.6% and a 63.72% success rate. Darout covers the Healthcare sector, focusing on stocks such as Incyte, Abivax SA Sponsored ADR, and BeOne Medicines.

Currently, the analyst consensus on Syndax Pharmaceuticals is a Strong Buy with an average price target of $38.67.

### Related Stocks

- [SNDX.US](https://longbridge.com/en/quote/SNDX.US.md)
- [BARC.UK](https://longbridge.com/en/quote/BARC.UK.md)
- [BCS.US](https://longbridge.com/en/quote/BCS.US.md)
- [INCY.US](https://longbridge.com/en/quote/INCY.US.md)
- [ABVX.US](https://longbridge.com/en/quote/ABVX.US.md)
- [ONC.US](https://longbridge.com/en/quote/ONC.US.md)
- [688235.CN](https://longbridge.com/en/quote/688235.CN.md)
- [BGNE.US](https://longbridge.com/en/quote/BGNE.US.md)
- [06160.HK](https://longbridge.com/en/quote/06160.HK.md)

## Related News & Research

- [Earnings Update: Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Just Reported And Analysts Are Trimming Their Forecasts](https://longbridge.com/en/news/295230452.md)
- [Barclays Sticks to Their Buy Rating for Syndax Pharmaceuticals (SNDX)](https://longbridge.com/en/news/284877520.md)
- [Madrigal Pharma director John C. Reed files initial beneficial ownership statement](https://longbridge.com/en/news/296270622.md)
- [Great Lakes Advisors LLC Acquires Shares of 66,924 Ionis Pharmaceuticals, Inc. $IONS](https://longbridge.com/en/news/296455358.md)
- [Septerna, Inc. (SEPN) Receives a Rating Update from a Top Analyst](https://longbridge.com/en/news/296029142.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**